Compare AMSC & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMSC | IOVA |
|---|---|---|
| Founded | 1987 | 2007 |
| Country | United States | United States |
| Employees | 400 | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2012 | 2008 |
| Metric | AMSC | IOVA |
|---|---|---|
| Price | $27.70 | $10.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $52.00 | $9.00 |
| AVG Volume (30 Days) | 596.7K | ★ 13.0M |
| Earning Date | 05-20-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1806.25 | 14.84 |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $900,000.00 | N/A |
| Revenue This Year | $34.98 | $47.74 |
| Revenue Next Year | $21.38 | $40.31 |
| P/E Ratio | $138.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.87 | $1.76 |
| 52 Week High | $70.49 | $9.36 |
| Indicator | AMSC | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 39.57 | 70.70 |
| Support Level | $26.88 | $3.82 |
| Resistance Level | $33.70 | N/A |
| Average True Range (ATR) | 1.02 | 0.42 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 14.47 | 86.11 |
American Superconductor Corp generates the ideas, technologies, and solutions that meet the world's demand for smarter, cleaner, and energy. Through its Windtec Solutions, the company enables manufacturers to launch wind turbines quickly, effectively, and profitably. Through its Gridtec Solutions, the company provides engineering planning services and grid systems that optimize network reliability, efficiency, and performance. The company's segment includes Grid and Wind. It generates maximum revenue from the Grid segment.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.